Medical Professionals
Patients with rare tumors need more answers.
Let’s unleash the possibilities.
We are committed to supporting the medical community who care for those with rare and devastating tumors. We know that every day matters for your patients, which is why our Medical Affairs team is dedicated to providing the information you need about our research, our pipeline, Expanded Access Programs, and more.
Focus Areas
We focus on developing treatment advances to improve the lives of people with rare and devastating tumors. Because the need is great, we are digging deep into the science behind our lead products, nirogacestat and mirdametinib. Our hope is to unlock their full potential across a range of conditions while simultaneously developing other promising molecules. As part of our approach, we are actively pursuing new licensing and partnership opportunities with other innovators to advance promising science as efficiently as possible.
Explore our pipeline
View presentations & publications
Explore our FDA-approved medicines
Expanded Access and Compassionate Use
SpringWorks is committed to developing safe and effective therapies for patients with severe rare diseases and cancer. We believe that, wherever possible, use of an investigational or unlicensed therapy for a patient as part of a clinical trial is preferable because clinical trials are designed to generate comprehensive safety and efficacy data that may lead to the approval of new medicines and consequently, to wider availability for patients in need.
In cases when a patient may not qualify for a clinical trial, there may be no trials available, or a patient has exhausted all available treatment possibilities, SpringWorks may be able to provide access to eligible patients under the supervision of the requesting healthcare provider through either our named patient program or our compassionate use program. This refers to the use of a SpringWorks investigational or unlicensed therapy outside of our clinical trials and prior to its commercial availability.
Investigator-Initiated Research
SpringWorks is committed to supporting Investigator-Initiated Research (IIR) to advance medical and scientific knowledge relating to its product candidates and current therapeutic areas of interest.
Medical Education and Grants
SpringWorks supports corporate memberships, medical education, and sponsorships to educate healthcare providers across the multidisciplinary team and to advance medical care and scientific research for patients with severe rare diseases and cancer.
SpringWorks Transparency and Data Sharing
SpringWorks is committed to sharing information about our clinical studies, including study results and data, to further scientific and medical research that informs treatment decisions and advances scientific knowledge to benefit patients. SpringWorks shares data following company policies, applicable laws, and regulatory authority requirements to maintain the privacy and confidentiality of research participants. Pertinent study data from completed or terminated registrational interventional clinical trials will be shared responsibly and ethically, guided by relevant external standards and internal policies and procedures. To learn more about our data-sharing policies or to inquire about making a data-sharing request, you can contact SpringWorks Medical Information in one of the following ways: 888-400-SWTX [7989], https://springworkstxmedical.com or medinfo@springworkstx.com.